Literature DB >> 29185283

Surgical Treatment of Neuroblastoma.

Ayelet Ben Barak1, Hana Golan2, Dalia Waldman2, Marc S Arkovitz3.   

Abstract

BACKGROUND: Neuroblastoma is the most common non-central nervous system (CNS) solid malignant tumor in children. The surgical treatment of high-risk neuroblastoma presents a challenge, and the benefits of aggressive surgical resection have been called into question.
OBJECTIVES: To examine our experience with surgical resection of neuroblastoma.
METHODS: We report on a retrospective chart review of our preliminary surgical experience in 25 patients with neuroblastoma who underwent surgery performed by a single surgeon at two institutions over a 3 year period. Demographic data, including stage of tumor and risk stratification, were recorded. Primary outcome was total gross resection. Patients were followed for 3 years after surgery.
RESULTS: We found that 80% of the patients, including those with high-risk neuroblastoma tumors, had total gross resection of their tumor with minimal operative morbidity and no mortality; 88% had greater than 90% resection of their tumor. Overall, 3 year survival was 84% (21/25).
CONCLUSIONS: Resection of neuroblastoma, even large, high-risk, bilateral tumors, was possible when performed by surgical teams with considerable experience.

Entities:  

Mesh:

Year:  2017        PMID: 29185283

Source DB:  PubMed          Journal:  Isr Med Assoc J            Impact factor:   0.892


  2 in total

1.  The Dramatic Consequences of an Accidental Ligation of the Celiac Trunk during Surgery Performed on a Child with Neuroblastoma.

Authors:  Patrycja Sosnowska-Sienkiewicz; Danuta Januszkiewicz-Lewandowska; Przemysław Mańkowski
Journal:  Int J Environ Res Public Health       Date:  2021-02-14       Impact factor: 3.390

2.  MicroRNA-145 overexpression inhibits neuroblastoma tumorigenesis in vitro and in vivo.

Authors:  Jing Zhao; Kai Zhou; Liang Ma; Huanyu Zhang
Journal:  Bioengineered       Date:  2020-12       Impact factor: 3.269

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.